Format

Send to

Choose Destination
Eur J Heart Fail. 2016 May;18(5):457-68. doi: 10.1002/ejhf.495. Epub 2016 Feb 11.

MicroRNAs in heart failure: from biomarker to target for therapy.

Author information

1
Department of Cardiology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
2
Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands.
3
Department of Cardiology, Heart Failure Research Centre, Academic Medical Centre, Amsterdam, the Netherlands.

Abstract

MicroRNAs (miRNAs) are increasingly recognized to play important roles in cardiovascular diseases, including heart failure. These small, non-coding RNAs have been identified in tissue and are involved in several pathophysiological processes related to heart failure, such as cardiac fibrosis and hypertrophy. As a result, miRNAs have become interesting novel drug targets, leading to the development of miRNA mimics and antimirs. MicroRNAs are also detected in the circulation, and are proposed as potential diagnostic and prognostic biomarkers in heart failure. However, their role and function in the circulation remains to be resolved. Here, we review the potential roles of miRNAs as circulating biomarkers and as targets for therapy.

KEYWORDS:

Antimir; Circulation; Heart failure; MicroRNAs

PMID:
26869172
DOI:
10.1002/ejhf.495
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center